Inke is an API manufacturer based in Spain. It holds 48 active US drug master files across a filed portfolio of 21 molecules. Its most recent recorded inspection, by US FDA, closed on 15 March 2023 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Spain, Spain | 3003663245 |
| Molecule | Regulators | Docs |
|---|---|---|
| Arformoterol | US FDA | 4 |
| Granisetron | US FDA | 4 |
| Ondansetron | US FDA | 4 |
| Aclidinium Bromide | US FDA | 2 |
| Aprepitant | US FDA | 2 |
| Clevidipine | US FDA | 2 |
| Fluconazole | US FDA | 2 |
| Formoterol | US FDA | 2 |
| Glycopyrronium | US FDA | 2 |
| Indacaterol | US FDA | 2 |
| Olanzapine | US FDA | 2 |
| Olodaterol | US FDA | 2 |
| Revefenacin | US FDA | 2 |
| Risperidone | US FDA | 2 |
| Rizatriptan | US FDA | 2 |
| Salmeterol | US FDA | 2 |
| Tetrabenazine | US FDA | 2 |
| Tiotropium | US FDA | 2 |
| Umeclidinium Bromide | US FDA | 2 |
| Vilanterol | US FDA | 2 |
| Zolmitriptan | US FDA | 2 |
Also appears on these molecule pages
Choose your molecules and target markets. Inke comes back tiered against every other supplier able to file there.
Start for free